Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial

医学 间皮瘤 腹膜间皮瘤 肿瘤科 内科学 培美曲塞 CDKN2A 临床终点 危险系数 临床试验 化疗 癌症 病理 顺铂 置信区间
作者
Dean A. Fennell,Amy King,Seid Mohammed,Alastair Greystoke,Sarah Anthony,Charlotte Poile,Nada Nusrat,Molly Scotland,Vina Bhundia,Amy Branson,Cassandra Brookes,Liz Darlison,Alan G. Dawson,Aarti Gaba,Margaret Hutka,Bruno Morgan,Amrita Bajaj,Cathy Richards,Peter Wells-Jordan,Anne Thomas,Dean A. Fennell,Amy King,Alastair Greystoke,Sarah Anthony,Sam Moody,Charlotte Poille,Nada Nusrat,Molly Scotland,Vina Bhundia,Amy Branson,Cassandra Brookes,Liz Darlison,Alan G. Dawson,Aarti Gaba,Margaret Hutka,Bruno Morgan,Amrita Bajaj,Cathy Richards,Peter Wells-Jordan,Adrian Nicolson,Judith Underwood,Azmina Sodha-Ramdeen,Caroline Cowley,Shaun Barber,Anne Thomas
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (3): 374-381 被引量:48
标识
DOI:10.1016/s1470-2045(22)00062-6
摘要

Genetically stratified therapy for malignant mesothelioma is unavailable. Mesotheliomas frequently harbour loss of the chromosome 9p21.3 locus (CDKN2A-MTAP), which is associated with shorter overall survival due to loss of the tumour suppressor p16ink4A, an endogenous suppressor of cyclin-dependent kinase (CDK)4 and CDK6. Genetic restoration of p16ink4A suppresses mesothelioma in preclinical models, underpinning the rationale for targeting CDK4 and CDK6 in p16ink4A-negative mesothelioma. We developed a multicentre, stratified, phase 2 trial to test this hypothesis.The MiST2 study was a single-arm, open-label, phase 2 clinical trial done two UK centres. Patients older than 18 years with any histologically confirmed subtype of mesothelioma (pleural or peritoneal) with radiological progression after at least one course of platinum-based chemotherapy were molecularly screened by immunohistochemistry for p16ink4A. Patients with p16ink4A-negative mesothelioma were eligible for inclusion in the study. Patients were required to have measurable disease by modified Response Evaluation Criteria in Solid Tumours version 1.1 for malignant mesothelioma, a predicted life expectancy of at least 12 weeks, and an Eastern Cooperative Oncology Group performance status score of 0-1. Patients received oral abemaciclib 200 mg twice daily, administered in 28-day cycles for 24 weeks. The primary endpoint was the disease control rate (patients with complete responses, partial responses, or stable disease) at 12 weeks. The null hypothesis could be rejected if at least 11 patients had disease control. The efficacy and safety populations were defined as all patients who received at least one dose of the study drug. The study is registered with ClinicalTrials.gov, NCT03654833, and is ongoing (but MiST2 is now closed).Between Sept 31, 2019, and March 2, 2020, 27 eligible patients consented to molecular screening. The median follow-up was 18·4 weeks (IQR 6·7-23·9). One patient was excluded before treatment because of a serious adverse event before study drug allocation. 26 (100%) of 26 treated patients were p16ink4A deficient and received at least one dose of abemaciclib. Disease control at 12 weeks was reported in 14 (54%) of 26 patients (95% CI 36-71). Grade 3 or worse treatment-related adverse events (of any cause) occurred in eight (27%) of 26 patients (diarrhoea, dyspnoea, thrombocytopenia, vomiting, urinary tract infection, increased alanine aminotransferase, ascites, chest infection or suspected chest infection, neutropenic sepsis, alopecia, blood clot left calf, fall [broken neck and collar bone], haemoptysis, lower respiratory tract infection, and pulmonary embolism). Grade 3 or worse treatment-related adverse events occurred in three (12%) of 26 patients (diarrhoea, thrombocytopenia, vomiting, increased alanine aminotransferase, and pulmonary embolism). Serious adverse events occurred in six (23%) of 26 patients, leading to treatment discontinuation in one (4%) patient (diarrhoea, urinary tract infection, chest infection, neutropenic sepsis, fall [broken neck and collar bone], haemoptysis, lower respiratory tract infection, and pulmonary embolism). One patient had a serious adverse event related to abemaciclib (diarrhoea). One (4%) of 26 patients died from an adverse event (neutropenic sepsis).This study met its primary endpoint, showing promising clinical activity of abemaciclib in patients with p16ink4A-negative mesothelioma who were previously treated with chemotherapy, and warrants its further investigation in a randomised study as a targeted stratified therapy.University of Leicester, Asthma UK and British Lung Foundation Partnership, and the Victor Dahdaleh Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我要文献发布了新的文献求助10
1秒前
1秒前
1秒前
量子星尘发布了新的文献求助10
4秒前
暴躁小龙发布了新的文献求助10
5秒前
张润泽完成签到 ,获得积分10
5秒前
6秒前
文档发布了新的文献求助10
6秒前
7秒前
9秒前
10秒前
10秒前
11秒前
12秒前
12秒前
烟花应助zwk采纳,获得10
14秒前
蔡芝艳关注了科研通微信公众号
14秒前
YI完成签到,获得积分10
17秒前
17秒前
大个应助科研通管家采纳,获得10
18秒前
18秒前
充电宝应助科研通管家采纳,获得10
19秒前
SYLH应助科研通管家采纳,获得20
19秒前
Ava应助科研通管家采纳,获得10
19秒前
丘比特应助科研通管家采纳,获得10
19秒前
情怀应助科研通管家采纳,获得10
19秒前
Hello应助科研通管家采纳,获得10
19秒前
Owen应助科研通管家采纳,获得10
19秒前
19秒前
su发布了新的文献求助10
21秒前
钟垠州完成签到 ,获得积分10
21秒前
21秒前
活力的妙之完成签到 ,获得积分10
21秒前
丘比特应助只想困瞌睡采纳,获得10
21秒前
小宋发布了新的文献求助10
22秒前
笃定发布了新的文献求助30
24秒前
淡墨完成签到,获得积分10
25秒前
今后应助清漪采纳,获得10
25秒前
zwk发布了新的文献求助10
26秒前
29秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158